Alvimopan (trade name Entereg) is a drug which behaves as a peripherally acting μ-opioid antagonist. With limited ability to cross the blood–brain barrier many of the undesirable side-effects of the opioid agonists such as constipation are minimized without affecting analgesia or precipitating withdrawals. The Food and Drug Administration reviewed the safety and efficacy data for alvimopan and approved its use in May 2008.
This page contains content from the copyrighted Wikipedia article "Alvimopan"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
